Hector Martinez Gonzalez, MD
Interventional Cardiology · Mayaguez, PRNPI 1902008352
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $189,060 of the $260,590 with a category attached, or 72.6%. 22 manufacturers reported payments, led by Johnson & Johnson at 52.9% of the total. Reporting peaked in 2021 at $65,211 and has fallen 71.0% since, to $18,917 in 2025. Among interventional cardiology clinicians in PR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 618 payments — averaging $421.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$138K
- Abbott$55K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$27K
- Boston Scientific$22K
- Medtronic$12K
- Terumo Medical Corporation$4K
- plus $3K from 16 others
What the payments were for
- Consulting fees$45,93018%
- Speaking & faculty fees$189,06073%
- Travel & lodging$8,7223%
- Food & beverage$16,8036%
- Gifts$750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 109 | $137,750 |
| Abbott | 122 | $54,550 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 69 | $27,075 |
| Boston Scientific | 135 | $21,888 |
| Medtronic(2 entities) | 109 | $12,211 |
| Terumo Medical Corporation | 3 | $4,040 |
| Boehringer Ingelheim | 8 | $611 |
| AstraZeneca | 13 | $449 |
| E.r. Squibb & Sons, L.L.C. | 9 | $435 |
| Edwards Lifesciences | 2 | $282 |
| Amgen | 6 | $245 |
| Merck | 3 | $192 |
| Bayer | 2 | $191 |
| PBG Puerto Rico LLC | 10 | $178 |
| Bayer Puerto Rico Inc. | 5 | $114 |
| Novartis | 5 | $110 |
| Chiesi USA, Inc. | 3 | $108 |
| Pfizer Pharmaceuticals LLC | 1 | $64 |
| Asahi Intecc USA, Inc. | 1 | $51 |
| Cordis US CORP. | 1 | $20 |
| AbbVie | 1 | $17 |
| Cardinal Health P.r. 120 Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$135,533
- LifeVest$25,704
- XIENCE SIERRA$9,892
- Dragonfly OCT$9,023
- Xience V coronary stent system$7,530
- SYNERGY$7,500
- AMPLATZER$7,200
- OPTIS$6,325
- COREVALVE EVOLUT R$5,418
- GENERAL - THERAPIES$3,000
- OMNILINK ELITE$3,000
- FFR LINK$3,000
- DRAGONFLY OPSTAR$2,800
- Perclose ProGlide suture mediated closure system$2,400
- ROTAPRO$2,000
- SUPERA$2,000
- XIENCE V$1,251
- XIENCE SKYPOINT$1,200
- OPTICROSS$1,000
- ONYX FRONTIER$415
How this compares
$260,590 in reported general payments places this provider in the 90th percentile of 39 interventional cardiology providers in Puerto Rico.
See all interventional cardiology providers in Puerto Rico →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 164 | $134,083 |
| XareltoRivaroxaban | 113 | $79,764 |
| BrilintaTicagrelor | 69 | $35,058 |
| Candesartan Cilexetil | 107 | $13,730 |
| EliquisApixaban | 19 | $10,185 |
| ClopidogrelClopidogrel Bisulfate | 528 | $7,055 |
| Ranolazine ErRanolazine | 64 | $6,729 |
| Rosuvastatin Calcium | 486 | $6,377 |
| Metoprolol Succinate | 298 | $5,231 |
| Doxazosin Mesylate | 163 | $4,637 |
| Ezetimibe | 163 | $3,662 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 126 | $2,521 |
| Losartan Potassium | 166 | $2,431 |
| Bumetanide | 46 | $1,882 |
| Irbesartan | 39 | $1,471 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Brilinta | $449 | $169,141233 claims |
| Johnson & JohnsonXarelto | $137,750 | $79,764113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 39 interventional cardiology providers in Puerto Rico.
Other interventional cardiology in Mayaguez
- Frantony Mercado CabreraMayaguez$12K
- Edgar Vazquez-VargasMayaguez$8K
- Damian Grovas AbadSan Juan$498K
- Eric Carro JimenezSan Juan$416K
- Alejandro Lopez MasPonce$142K
- Ricardo SantiagoManati$131K
- Edwin I Perez MarreroSan Juan$129K
- Pedro Colon HernandezCaguas$128K
- Enrique Hernandez VilaPonce$44K
- Ismael Ortiz-CartagenaBayamon$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.